Compare VRTX & PANW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | PANW |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Computer peripheral equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 126.9B |
| IPO Year | 2006 | 2012 |
| Metric | VRTX | PANW |
|---|---|---|
| Price | $481.28 | $167.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 40 |
| Target Price | ★ $537.64 | $216.38 |
| AVG Volume (30 Days) | 1.3M | ★ 12.2M |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 15.32 | 1.07 |
| Revenue | ★ $2,488,652,000.00 | $2,273,100,000.00 |
| Revenue This Year | $10.79 | $24.94 |
| Revenue Next Year | $10.14 | $19.95 |
| P/E Ratio | ★ $32.16 | $154.10 |
| Revenue Growth | ★ 46.20 | 29.04 |
| 52 Week Low | $362.50 | $139.57 |
| 52 Week High | $519.68 | $223.61 |
| Indicator | VRTX | PANW |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 57.74 |
| Support Level | $428.47 | $165.21 |
| Resistance Level | $503.88 | $170.49 |
| Average True Range (ATR) | 15.72 | 5.22 |
| MACD | 0.49 | 2.93 |
| Stochastic Oscillator | 51.78 | 98.49 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.